That's a nice fiction novel. You should try to get it published for women in nail salons to read.
If it gets a miracle approval in the tiny UK market, then they will have to run 2 pediatric trials for final approval.
Then, 2 years and $50 million later, they will have to get NICE to pay for it ( which will never happen at around $200k IMO)
Furthermore, the UK market is far from world-wide markets. Also, there is only ONE form of cancer, GBM... All other types will have to pass through rigorous and very expensive clinical trials.
Lastly, NWBO only licenses DCVAX form UCLA, they don't own the IP, just some process patents. Advent bills for the service, deducts all costs and gets a guaranteed 15% profit built in to the CDMO (cost plus 15%) contract. NW and UCLA split whatever is left over. That split is still unknown to me and not public. So if they got 1,000 patients in the UK market , they would probably do about $25 Million in total sales. ( BEST CASE SCENARIO, mind you) Minus all the salaries and expenses. Current market cap is almost $400 MILLION currently, fully diluted.. This stock is going nowhere but down, in my humble opinion.
Market Data 
Markets 
